AM-111
Phase 3Small molecule
AM-111 is one of 50 small molecule programs targeting Sudden Sensorineural Hearing Loss. It is currently in Phase 3.
3
Indications
3
Total Trials
0
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
46 competitors in Hearing Loss
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Cymbalta
Alnylam PharmaceuticalsApproved
Decadron
AAspen Global Incorporated
Approved
Plaquenil
Alnylam PharmaceuticalsApproved
Cipro
BayerApproved
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Rayos
RRoxane Laboratories
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Statin
Bristol-Myers SquibbApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AM-111. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAuris Medical AG